Farnesoid X Receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through down-regulation of HER2 expression

Tamoxifen (Tam) treatment is a first-line endocrine therapy for estrogen receptor α (ERα) positive breast cancer patients. Unfortunately, resistance frequently occurs and is often related with overexpression of the membrane tyrosine kinase receptor HER2. This is the rationale behind combined treatme...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncogene
Auteurs principaux: Giordano, Cinzia, Catalano, Stefania, Panza, Salvatore, Vizza, Donatella, Barone, Ines, Bonofiglio, Daniela, Gelsomino, Luca, Rizza, Pietro, Fuqua, Suzanne A. W., Andò, Sebastiano
Format: Artigo
Langue:Inglês
Publié: 2011
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4482257/
https://ncbi.nlm.nih.gov/pubmed/21499302
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2011.124
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires